Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
Authors:
- Ross A. SooRSRoss A. Soo
- Richie SoongRSRichie Soong
- Sai-Hong I. OuSOSai-Hong I. Ou
- 1 November 2012
- journal article
- review article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 7 (11) , 1625-1630
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Temporal Dissection of Tumorigenesis in Primary CancersCancer Discovery, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human CholangiocarcinomaPLOS ONE, 2011
- Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcriptsGenome Biology, 2009
- Transcriptome sequencing to detect gene fusions in cancerNature, 2009
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005